Company news

Tempus Ai, Inc. (NASDAQ:TEM) news

Tempus Ai, Inc. news releases on 6ix. Latest, Oct 1, 2026: Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical…

Tempus Ai, Inc. (NASDAQ:TEM) news

Press releases & updates

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

Tempus Reports Second Quarter 2026 Results

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

Tempus to Report Second Quarter 2026 Financial Results on July 30

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology

Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for "Best Overall Health Informatics Solution"

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus Reports First Quarter 2026 Results

Tempus to Host Inaugural Investor Day on May 29, 2026

Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

Tempus to Report First Quarter 2026 Financial Results on May 5

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

Tempus Reports Fourth Quarter and Full Year 2025 Results

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24